New Federal Market Access Restrictions: Optimizing Manufacturer Strategies as PBMs Gain Power

Key Takeaways

• PBMs must pass 100% rebates to employer plans
• Tier placement and step therapy will intensify
• Flat fees may replace rebate revenue for PBMs
• Manufacturers should shift to outcomes‑based contracts
• Vertical integration ties formulary access to preferred pharmacies

Pulse Analysis

The 2026 Consolidated Appropriations Act marks a watershed moment for pharmacy benefit managers, mandating full rebate pass‑through to ERISA‑governed employer plans. By eliminating spread‑pricing, the law forces PBMs to seek alternative revenue streams, prompting a surge in formulary manipulation tactics such as higher tier placement and multi‑step therapy requirements. This shift not only raises the administrative burden on prescribers but also amplifies the importance of net‑cost modeling for drugmakers, who must now demonstrate clear value beyond traditional rebate discounts.

For manufacturers, the new transparency regime opens a dual pathway: larger, diversified firms can leverage scale to negotiate portfolio‑wide contracts anchored in real‑world evidence, while niche players may find leverage in single‑asset negotiations that highlight distinct clinical outcomes. Outcomes‑based contracts are poised to replace many rebate arrangements, tying payments directly to measurable patient results and reducing PBM exposure to underperforming therapies. Additionally, the rise of PBM‑owned private‑label biosimilars adds a competitive layer, urging innovators to focus on therapeutic areas where biosimilar substitution is less economically viable.

Strategically, pharma companies should overhaul gross‑to‑net pricing models, incorporate flat‑fee structures where appropriate, and segment strategies by payer type, recognizing that Medicare and self‑funded employer plans will respond differently to the reforms. Investing in robust data analytics to support performance‑based agreements will be critical, as will proactive engagement with PBMs to influence formulary decisions before the 2028 implementation deadline. Early adaptation can convert regulatory pressure into a sustainable competitive advantage in an increasingly PBM‑centric market.